刮除术联合咪喹莫特乳膏对比手术切除治疗结节性基底细胞癌:随机临床试验的二次分析
该二次分析基于SCIN随机临床试验,纳入145例原发性结节性基底细胞癌患者,比较刮除术联合5%咪喹莫特乳膏与手术切除的5年无治疗失败概率。结果显示联合治疗组5年无失败概率为77.8%,手术切除组为98.2%,相对风险为15.93,无法得出联合治疗非劣于手术切除的结论。
要点
- 刮除术联合咪喹莫特治疗结节性基底细胞癌5年无失败概率为77.8%,低于手术切除的98.2%。
- 联合治疗组15例治疗失败,其中5例发生在治疗后1至5年;手术组仅1例失败。
- 该结果可用于向患者说明结节性基底细胞癌不同治疗方案的获益与权衡。
核心结论
- 刮除术联合5%咪喹莫特乳膏在5年时疗效显著低于手术切除,不能得出其非劣于手术切除的结论。
研究设计与样本
- SCIN随机临床试验的二次分析,2016年1月1日至2017年11月30日在荷兰2个门诊皮肤科开展。
- 纳入145例原发性、组织学证实的结节性基底细胞癌患者(直径4-20 mm),随机分配至刮除术联合5%咪喹莫特组(n=73)或手术切除组(n=72)。
- 主要结局为5年无治疗失败概率,采用Kaplan-Meier分析,并计划意向性分析和符合方案分析。
主要发现
- 刮除术联合咪喹莫特组5年无治疗失败概率为77.8%(95% CI,65.7%-86.0%),手术切除组为98.2%(95% CI,88.0%-99.8%)。
- 治疗失败的相对风险为15.93(95% CI,2.10-120.64),95% CI未排除非劣效界值5.22。
- 联合治疗组共15例治疗失败(其中5例发生在治疗后1至5年),手术组1例失败。
- 20例患者死于与基底细胞癌无关的原因,竞争风险回归的子风险比为16.16(95% CI,2.18-119.72)。
临床怎么用
- 向结节性基底细胞癌患者说明刮除术联合咪喹莫特与手术切除的5年疗效差异及权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interest in noninvasive treatment of basal cell carcinoma (BCC) has been increasing. For superficial BCC, it has been demonstrated that imiquimod cream, 5%, has high long-term efficacy, but for nodular BCC (nBCC), long-term evidence is sparse. OBJECTIVES: To evaluate whether superficial curettage (SC) followed by imiquimod cream, 5%, is noninferior to surgical excision (SE) in nBCC after 5 years of treatment. DESIGN, SETTING, AND PARTICIPANTS: In this secondary analysis of the noninferiority Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma (SCIN) randomized clinical trial, patients with a primary nBCC of 4 to 20 mm were assigned to either SC plus imiquimod, 5%, or SE between January 1, 2016, to November 30, 2017, at 2 outpatient dermatology departments in the Netherlands. The primary outcome of the SCIN trial was the 1-year probability of remaining free from treatment failure; the prespecified secondary trial outcomes were the probability after 5 years of follow-up, completed September 7, 2022. Both an intention-to-treat analysis and per-protocol analysis were planned. INTERVENTION: SC plus imiquimod vs SE. MAIN OUTCOMES AND MEASURES: The 5-year probability of remaining free from treatment failure (ie, freedom from recurrence; with 95% CI) was estimated with Kaplan-Meier analysis using data on treatment response from 3 planned follow-up visits at 3 months and 1 and 5 years after the end-of-treatment date. Additional analyses accounting for death as competing risk were also performed. RESULTS: A total of 145 patients (77 [53.1%] male; median age, 68 [IQR, 31-89] years) with a primary, histologically proven nBCC were randomized to treatment with SC plus imiquimod (n = 73) or SE (n = 72). In total, 15 treatment failures occurred in the SC plus imiquimod group (5 treatment failures occurred between 1 and 5 years after treatment) and 1 in the SE group. The 5-year probability of remaining free from treatment failure was 77.8% (95% CI, 65.7%-86.0%) after SC plus imiquimod and 98.2% (95% CI, 88.0%-99.8%) after SE. The relative risk of treatment failure was 15.93 (95% CI, 2.10-120.64). The 95% CI does not exclude the noninferiority margin of 5.22. Death due to causes unrelated to BCC occurred in 20 patients, and the subhazard ratio from competing risk regression was 16.16 (95% CI, 2.18-119.72). CONCLUSIONS: This secondary analysis of a randomized clinical trial found that although it cannot be concluded that SC plus imiquimod is noninferior to SE, SC plus imiquimod was substantially less effective at 5 years after treatment. Most treatment failures occurred in the first year after treatment, and the probability of tumor-free survival 5 years after treatment with SC plus imiquimod was still 77.8%. The information in this trial can be used to counsel patients on the relative benefits and trade-offs of the different treatment options for nBCC. TRIAL REGISTRATION: ClinicialTrials.gov Identifier: NCT02242929.
引用
- Verkouteren BJA, Nelemans PJ, Sinx KAE, et al. Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2025. PMID: 39878970. doi:10.1001/jamadermatol.2024.5572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。